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Abstract
Background: The long acting β2-agonists, salmeterol and formoterol, have been recommended,
by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We
reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in
patients with poorly reversible COPD.
Methods: After searching MEDLINE, EMBASE, HealthSTAR, BIOSIS Previews, PASCAL, ToxFile,
SciSearch, the Cochrane Library, and PubMed, as well as Web sites, selected journals, reference
lists, and contacting drug manufacturers, two reviewers independently screened reports of
randomised controlled trials of parallel or crossover design lasting four weeks or longer and
including patients with a forced expiratory volume in one second (FEV1) ≤ 75% of predicted, a ratio
of FEV1 to forced vital capacity (FVC) ≤ 88% of predicted, and < 15% improvement from baseline
FEV1 after a dose of a β2 agonist. We included trials comparing salmeterol or formoterol with
placebo or with ipratropium bromide and reporting one of these outcomes: lung function; exercise
capacity; quality of life scores; dyspnea; exacerbations; rescue inhaler use; incidence of tachycardia,
hypokalemia, or dry mouth. Two reviewers assessed the quality of included reports using the Jadad
scale and allocation concealment, and abstracted data.
Results: Twelve trials satisfied our inclusion criteria; eight were high quality (Jadad score >2) and
four were low quality (≤ 2). The adequacy of allocation concealment was unclear in all of them. We
did not perform a meta-analysis due to differences in trial design and how outcomes were
reported.
Two trials comparing salmeterol with ipratropium did not detect differences; one trial comparing
formoterol and ipratropium described greater improvement with formoterol in morning PEFR
(15.3 versus 7.1 l/min, p = 0.040).
Of twelve trials comparing long acting β2 agonists with placebo, six reported no improvement in
exercise capacity, eleven reported improvements in FEV1 lung function (one reported no
improvement), six reported less rescue inhaler usage (one reported no difference) and five
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reported improved dyspnea scores (two reported no improvement). Differences in quality of life
were detected in one salmeterol trial ; however, two salmeterol, and one formoterol trial reported
no differences. Adverse effects of interest were not reported.
Conclusion: In terms of clinical outcomes and safety, we could not find convincing evidence that
salmeterol and formoterol have demonstrated advantages to ipratropium, a less expensive drug,
for patients with stable COPD and poor reversibility. Compared to placebo, we found evidence of
reduced rescue inhaler usage and improved spirometric outcomes without a significant impact on
quality of life or exercise capacity.
Background
Bronchodilators are the primary agents used to manage
chronic obstructive pulmonary disease (COPD). They
modestly improve forced expiratory volume in one sec-
ond (FEV1) and reduce dynamic hyperinflation; breath-
lessness may lessen and exercise tolerance increase despite
little improvement in spirometric measurements [1]. The
bronchodilators currently available for COPD include β2
agonists (e.g., salbutamol and salmeterol), anticholiner-
gics (e.g., ipratropium bromide) and methylxanthines
(e.g., theophylline).
According to the Canadian guidelines for the treatment of
stable COPD [2] first line treatment consists of ipratro-
pium, two to four doses three to four times daily, plus a
short acting β2 agonist administered on an "as needed"
basis. If the patient uses substantial amounts of short act-
ing β2 agonists, or if the symptoms are greater at night
than in the early morning, a long acting β2 agonist (salm-
eterol or formoterol) is added twice daily. However,
recently some have recommended the latter as first line
agents for stable COPD [3], [4-7] potentially replacing the
less expensive ipratropium [4], [5-8].
Several trials have demonstrated the usefulness of salme-
terol and formoterol for the management of COPD[8], [9-
11]. According to a 1998 meta-analysis [12], in patients
with non-reversible COPD these agents produce small
increases in FEV1; however, these changes alone may not
correlate highly with symptom relief [13]. The authors of
the meta-analysis suggested that these drugs be prescribed
only for patients who find they provide definite clinical
improvement: reduced breathlessness or better exercise
capacity. All three trials in the meta-analysis [10,14-16].
compared long acting β2 agonists with placebo. Since
then, other studies of these agents in COPD, including
comparisons with anticholinergics [8,11] have appeared
in the literature.
Canadian provincial drug plan managers have noted a
substantial increase in the use of salmeterol and formot-
erol in recent years, an observation supported by data
from International Medical Services Canada, which col-
lects information on Canadian patterns of drug prescrib-
ing and estimates use: between 1997 and 2001, the use of
salmeterol and formoterol for COPD increased 1,150%
and 1,975%, respectively, whereas the use of ipratropium
for COPD decreased by 37% [17].
In light of the new trials and the recent changes in pre-
scribing practices, we undertook a systematic review to
evaluate the efficacy and safety of long acting β2 agonists
when compared with placebo or anticholinergic agents in
patients with stable, poorly reversible, COPD.
Methods
Searching
We obtained published literature and conference abstracts
for this document from two separate sources: (1) search
results from the CCOHTA's published health technology
review "Long-acting β2-agonists for maintenance therapy
of stable chronic obstructive pulmonary disease: a system-
atic review"; and, (2) search results from CCOHTA's
ongoing clinical review on long-acting β2-agonists for
maintenance treatment of stable chronic obstructive pul-
monary disease in mixed population. The first search was
performed on MEDLINE®, EMBASE®, HealthSTAR, BIOSIS
Previews® in June 2001 using a sensitive search strategy.
The second search performed in December 2002 had a
more focused search strategy and included PASCAL, Sci-
Search and ToxFile databases in addition to MEDLINE®,
EMBASE® and BIOSIS Previews® databases. As designed in
the search strategy, this search captured all the studies
included in CCOHTA's published review as well as some
additional trials published since previous search date.
Search details for both searches can be found in Appendix
2 [see Additional file 2]. Regular alerts have been estab-
lished on these databases to capture new studies and are
ongoing in 2004. Parallel searches were performed and
updated in PubMed and the Cochrane Library. In addi-
tion, we periodically searched Web sites of clinical trial
registries and health technology assessment (HTA) and
related agencies. Google™ and other search engines were
used to retrieve conference abstracts of major respiratory
associations. We also hand searched selected journals and
documents in the library of the Canadian Coordinating
Office for Health Technology Assessment and the bibliog-
raphies of retrieved reports. As well, we contacted theBMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
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Canadian offices of the manufacturers of salmeterol and
formoterol for nonconfidential information on unpub-
lished studies.
Selection
Two reviewers (D R H and V K S) worked independently
on these phases of the study. Disagreements were resolved
by discussion and consensus; a neutral third party (M B)
was consulted when necessary.
The reviewers evaluated the 504 unique citations by
reviewing titles and abstracts, discarding those deemed
irrelevant (e.g., case reports, review articles, and studies
unrelated to the use of β2 agonists for maintenance treat-
ment of stable COPD). They then selected all reports of
randomised controlled trials (RCTs) comparing salme-
terol or formoterol with placebo or an anticholinergic
agent, with or without the additional use of short acting
β2 agonists. No restrictions were placed on dosage, but
the trials had to be of either parallel or crossover design,
have lasted four weeks or longer, and have included
patients that met each of the following criteria.
• Non-asthmatic.
• Stable COPD: no infections, exacerbations, or hospital-
izations in the past month.
• FEV1 ≤ 75% of predicted.
• Ratio of FEV1 to forced vital capacity (FVC) ≤ 88% of
predicted.
• After a dose of a short or long acting β2 agonist < 15%
improvement in FEV1.
Since bronchodilators are much more efficacious in
asthma than in COPD, including patients with asthma
would have influenced the findings. It may be difficult to
determine whether chronic airflow obstruction with rela-
tively large responses to short acting β2 agonists repre-
sents COPD with reversibility or asthma with incomplete
reversibility. A suggestive feature in the differential diag-
nosis of COPD is irreversible airflow limitation.[18] To
better reflect this and to minimize the chance of including
patients with asthma, we excluded those trials in which
the average FEV1 response to a bronchodilator was greater
than or equal to 15%.
In addition, the trials had to have investigated one of the
following outcomes.
• Lung function, including FEV1 and peak expiratory flow
rate (PEFR).
• Exercise capacity: six minute or shuttle walking test.
• Health related quality of life (QoL).
• Dyspnea, including symptom diary scores.
• Exacerbations of COPD.
• Rescue use of salbutamol, a short acting β2 agonist.
• Adverse effects, including tachycardia, hypokalemia,
and dry mouth.
Validity assessment
The reviewers independently scored the quality of the
included trial reports using a five-point scale described by
Jadad [19], which assigns zero to two points each for
appropriateness of randomization and double blinding
and zero to one point each for reporting on withdrawals
and dropouts; low scores are associated with exaggerated
estimates of benefit. Concealment of allocation to treat-
ment was also categorized as adequate, inadequate, or
unclear.
Data abstraction
The reviewers independently recorded characteristics of
the trials and patients, as well as details of the interven-
tions and outcomes. When outcome data were available
only graphically, each reviewer estimated values, and the
means of the two estimates were reported.
Quantitative data synthesis
When possible, we calculated mean differences with 95%
confidence intervals (CIs) for continuous outcomes and
odds ratios (ORs) with 95% CIs for binary outcomes for
individual trial data using Statistics with Confidence soft-
ware [20], We used intention-to-treat data when available
and otherwise end point data for patients completing the
trials. Qualitative data were recorded descriptively. We
had intended to do a meta-analysis, pooling data on out-
comes of interest. This approach is useful when the sam-
ples of individual studies are too small for detection of an
effect and when results from several trials disagree in mag-
nitude and direction of effect [21]. However, it is only
appropriate when the trials are clinically homogeneous.
We found that even commonly measured outcomes, such
as FEV1, could not be combined by meta-analysis because
of differences in how they were reported. For example, in
the six trials comparing salmeterol with placebo, FEV1
was reported as a mean change in percent predicted[16], a
mean change overall[15], a mean difference between trial
arms[10], no difference (without data)[22], baseline and
overall FEV1 (after 24 hrs without medication)[8] and as
an 0 to 12 hour area-under-the-curve (FEV1-AUC)BMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
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function[23] We were not successful in obtaining more
data from study authors. We also had concerns about the
meta-analysis of data from trials of parallel and crossover
design[24] and differences in spirometry protocols
including allowable medications. Therefore, we decided
on a best evidence synthesis approach [25] instead.
Results
Trial Flow
Both reviewers agreed to tentatively accept 35 of the 58
potentially relevant reports. After further evaluation one
reviewer disagreed with including 14 of the 35, which
resulted in a moderate level of agreement (Kappa = 0.58;
95% CI 0.39 to 0.78). Discussion revealed that this differ-
ence related primarily to confusion surrounding interpre-
tation of one of the criteria for eligibility, and ultimately
the other reviewer agreed to reject the disputed reports.
The reviewers then independently selected the same nine
reports [8,10,14-16,22,23,26,27] for final inclusion. Fig-
ure 1 illustrates the study selection process. The updated
search strategy identified 24 additional potentially rele-
vant reports. Of these, four reports were independently
selected based on the inclusion criteria. There were no dis-
agreements. Appendix 1 [see Additional file 1] presents all
of the 69 reports excluded with reasons.
Study characteristics
The 13 reports were of 12 trials, all funded by manufactur-
ers of the drugs. One report [14] describes outcomes in a
subset of patients fully described in another report [10].
One reports was a conference abstract [22]; the other
twelve reports were journal articles. Duplicate reports
were used as a source of supplementary information.
Based on the reports, eight of the trials [8,15,16,23,26-29]
were of high quality (score > 2) and four[10,22,30,31] of
low quality (score ≤ 2). Concealment of the allocation
sequence was unclear from all of the trial reports. The
reviewers agreed completely about quality. Table 1
presents details of the trials and patients.
Data synthesis
Comparative efficacy of long acting β2 agonists and anticholinergic 
agents
Three trials [8,23,26] that compared long acting β2 ago-
nists and anticholinergic agents were identified. Two 12
week trials compared salmeterol, ipratropium, and pla-
cebo [8,23].; however, only one trial [8] reported data for
FEV1 and transition dyspnea index (TDI) scores for the
subset of patients that met our inclusion criteria, and the
data were presented graphically. No significant differences
(p > 0.05) between the salmeterol and ipratropium
groups were observed in the change in FEV1 from base-
line, in TDI scores, or in the rescue use of salbutamol [8].
In a 12 week trial [26] formoterol produced significantly
greater improvement in morning PEFR from baseline to
endpoint than ipratropium (15.3 versus 7.1 l/min, p =
0.040). However, the differences between the active treat-
ment groups were not significant (p > 0.05) for percent
predicted FEV1 (13% versus 7%, p > 0.05), percent pre-
dicted FVC (8% versus 8%, p > 0.05), improvement in
breathlessness score (-0.21 versus -0.29, p > 0.05), or
improvement in the St. George's Respiratory Question-
naire (SGRQ) total score (0.0 versus -0.5, p > 0.05). Data
on adverse effects of interest, including tachycardia,
hypokalemia, and dry mouth, were not available from the
reports.
Comparative efficacy of long acting β2 agonists and placebo
Ten trials [8,10,14-16,22,23], [28-31] had salmeterol and
placebo treatment arms; the other two [26,27]. had for-
moterol and placebo arms. Table 2 and the following text
summarize outcome data only for the patients that met
our inclusion criteria.
Lung function
FEV1
As table 2 shows, the changes in FEV1 from baseline to
endpoint differed significantly (p < 0.05) between the sal-
meterol and placebo groups in eight of ten trials and
between the formoterol and placebo groups in two trials.
FVC
Five trials[15,23,26,28,31] reported on this outcome. In
one 4+4 week (4 weeks then crossover then 4 additional
weeks) trial [15] the increase in FVC was significantly
greater with salmeterol than with placebo six hours after a
single dose (200 versus 30 ml, 95%CI for difference: 40 to
290) but not after four weeks of treatment (150 versus 130
ml, 95%CI for difference: -180 to 220). In one 12 week
study [23] the change in FVC was significantly greater (p <
0.001) for salmeterol (and ipratropium) than for placebo
on day 1, there was no loss of response during treatment,
and after four weeks the morning predose values were sig-
nificantly greater in the patients treated with either active
drug (data not reported). In the other 12 week trial [26]
the percent predicted FVC was significantly increased by
the end of formoterol treatment, compared with placebo
treatment, by 8% versus -0.4% (p = 0.02). In one 52 week
trial).)[28], the change in mean FVC measured 12 hours
after treatment was 86 ml greater (p = 0.004) in salmeterol
recipients. The difference in mean change in FVC at 52
weeks was 200 ml between groups. In an 8 week trial[29],
the mean increase in FVC was 280 ml in the salmeterol
group compared to a fall of 8 ml in the placebo group (p
< 0.05).BMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
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PEFR
Three trials[16,26,28].).) reported on this outcome. In
one four week trial [16] salmeterol treatment compared
with placebo treatment produced a mean treatment differ-
ence in morning values of 12 l/min (238 compared with
226 l/min, 95%CI for difference: 6 to 17; p < 0.001); a sta-
tistical difference for evening values was not detected [242
(95%CI: 222 TO 262) and 237 (95% CI: 217 to 257) l/
min for salmeterol and placebo, p > 0.1]. The diurnal var-
iation was significantly lower during salmeterol treat-
ment, at 3 (95%CI: -0.9 to 6.9) versus 11 (95%CI: 7.1 to
14.9) l/min; however, the mean treatment difference was
only 7 (95%CI: 3 to 11) l/min. In the other trial, lasting
12 weeks [26], the change in morning PEFR was signifi-
cantly greater by the end of formoterol (or ipratropium)
treatment compared with placebo treatment: 15.3 versus -
0.9 l/min (p < 0.001). In one 52 week trial).)[28], the
change in mean PEF values differed significantly (p <
0.0001) for salmeterol treatment, at 257 l/min (95%CI:
253 to 261) versus placebo, at 242 l/min (95%CI: 238 to
246).
Exercise capacity
Results (but not always data) for six minute walk tests
were reported from six trials [8,10,15,22,26,29]. None of
the trials found statistically significant differences
between salmeterol and placebo therapy, although one 12
week trial[8] found that at week 10 the patients receiving
ipratropium walked a mean of 14 (95%CI: 0.3 to 27.7)
yards farther in six minutes than those receiving placebo;
there were no differences in prewalk or postwalk breath-
lessness between the treatment groups. The only other
Flow diagram of RCT screening and selection procedure Figure 1
Flow diagram of RCT screening and selection procedure. Process through which reports were selected from those 
potentially relevant. RCT = randomised controlled trial; ROAD = reversible obstructive airways disease; FEV1 = forced expir-
atory volume in one second.
Reports excluded by screening (n = 23)
Studies included patients with ROAD 
(n = 16), had no control group (n = 3), 
lasted less than four weeks (n = 1), had 
no comparator of interest (n = 1), or were 
retrospective (n = 1) or an economic 
evaluation without data of clinical interest 
(n = 1).
Reports retrieved for more 
detailed evaluation (n = 35)
Potentially relevant reports identified and 
screened for retrieval  (n = 58)
Reports excluded by discussion (n = 14)
Studies had no information about improvement in 
FEV  after a dose of a ß  agonist (n = 5), lasted 
less than four weeks (n = 4), did not include a 
comparator of interest (n = 4), or included patients 
with ROAD (n = 1).
12
Potentially appropriate reports for 
inclusion in systematic review 
(n = 21)
Reports excluded by further evaluation (n = 7)
Studies lasted less than four weeks (n = 4), were 
duplicate reports (n = 2), or analysed a published 
study retrospectively (n = 1).
Reports left for further investigation 
(n = 14) 
Reports describing RCTs included 
in the review (n = 9)
Reports rejected  (n = 5) 
Studies lasted less than four weeks (n = 4) or 
reported on a study already included (n = 1).BMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
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Table 1: Characteristics of included randomised, double blind, controlled trials of long acting β2 agonists in maintenance therapy for 
chronic obstructive pulmonary disease (COPD)
First author, year of 
publication, design
Trial quality Patients meeting inclusion 
criteria
Interventions Outcomes investigated Notes
Ulrik, 1995[16] 
Crossover
3 66 current smokers with FEV1 
of 1–2 L (< 60% of predicted) 
and FEV1/FVC < 60% of 
predicted. FEV1of <15% or 300 
ml after salbutamol
Salmeterol (50 µg twice daily) 
or placebo for 4+4 weeks; no 
crossover washout.
FEV1, PEFR, daytime and night-
time symptom scores, rescue 
use of salbutamol.
Two week run in. 
Methylxanthines, 
corticosteroids (short oral 
courses) allowed.
Newman, 1996[22] 
(abstract) Crossover
2 42 patients with mean FEV1 of 
0.93 L (35% of predicted) and 
no response to oral steroids.
Salmeterol (100 µg twice daily) 
or placebo for 8+8 weeks.
FEV1, FVC, six minute walk test 
and Borg dyspnoea 
assessment,[26] daytime and 
night-time symptom scores, 
rescue use of salbutamol, 
proportion of days unable to 
perform normal activity, 
incidence of adverse events 
and COPD exacerbations.
Two week run in. Salbutamol 
rescue allowed.
Grove, 1996[15] 
Crossover
3 29 patients with FEV1 25%–75% 
of predicted and 5%–15% 
reversibility with 200 µg of 
salbutamol.
Salmeterol (50 µg twice daily) 
or placebo for 4+4 weeks; 
one1 week crossover washout.
FEV1, FVC, TLC, RV, 6 minute 
walk test and exertion on Borg 
scale, oxygen uptake.
At least one week run in. 
Inhaled corticosteroids, 
anticholinergics, oral 
theophylline allowed.
Boyd, 1997[10] 
Parallel
2 674 patients with FEV1 ≤ 70% 
and FEV1/FVC ratio ≤ 60% of 
predicted and 5%–15% 
reversibility of FEV1 with 400 
or 800 µg of salbutamol.
Salmeterol (50 or 100 µg twice 
daily) or placebo for 16 weeks.
FEV1, six minute walk test and 
Borg dyspnoea assessment, 
daytime and night-time 
symptom scores, rescue use of 
salbutamol.
Two week run in. Medications 
other than β2 agonists allowed.
Jones, 1997[14] 
Parallel
2 283 patients with FEV1 ≤ 70% 
and FEV1/FVC ratio ≤ 60% of 
predicted; 5%–15% reversibility 
of FEV1 with 400 or 800 µg of 
salbutamol.
Salmeterol (50 or 100 µg twice 
daily) or placebo for 16 weeks.
HRQoL with SGRQ27 and SF-
36[28].
Two week run in. Medications 
other than β2 agonists allowed.
Mahler, 1999[8] 
Parallel
3 145 patients with FEV1 ≤ 65% 
and FEV1/FVC ratio ≤ 70% of 
predicted; ≤ 15% reversibility 
of FEV1 with short acting 
β2agonist; grade 1 baseline 
severity of breathlessness.
Salmeterol (42 µg twice daily) 
or ipratropium bromide (36 µg 
four times daily) or placebo for 
12 weeks.
FEV1 AUC, six minute walk 
test, daytime and night-time 
symptom scores, dyspnoea on 
BDI and TDI,[29] supplemental 
use of salbutamol, HRQoL on 
CRDQ,[30] COPD 
exacerbations.
Run in six hours to three days. 
Prednisone (≤ 10 mg) or 
equivalent or inhaled 
corticosteroids allowed.
Rennard, 2001[23] 
Parallel
3 179 patients with FEV1 ≤ 65% 
and FEV1/FVC ratio ≤ 70% of 
predicted; ≤ 12% reversibility 
of FEV1 with salbutamol; score 
≥ 1 on MMRC five point 
dyspnoea scale.
Salmeterol (42 µg twice daily) 
or ipratropium (36 µg four 
times daily) or placebo for 12 
weeks.
FEV1 and FVC AUC, dyspnoea 
on BDI and TDI, six minute 
walk test and Borg dyspnoea 
assessment, symptom scores, 
QoL on CRDQ, COPD 
exacerbations.
Corticosteroids, inhaled and 
oral (< 10 mg/d), allowed.
Rossi, 2002[27] 
Parallel
3 418 patients with FEV1 < 70% 
and FEV1/FVC ratio ≤ 88% of 
predicted; < 15% reversibility 
of FEV1 with short acting 
β2agonist; grade 1 baseline 
severity of breathlessness.
Formoterol (12 or 24 µg twice 
daily) or placebo or oral slow 
release theophylline for 12 
months.
FEV1 AUC. Inhaled corticosteroids and 
rescue use of salbutamol 
allowed.
Stahl, 2002[26] 
Parallel
3 183 patients with FEV1 < 60% 
and FEV1/FVC < 70% of 
predicted; < 12% reversibility 
of FEV1 after single dose of 
formoterol.
Formoterol (18 µg twice daily) 
or ipratropium (80 µg three 
times daily) or placebo for 12 
weeks.
FEV1, FVC, PEFR, shuttle 
walking test, morning and 
evening symptom scores, 
HRQoL on SGRQ.
Inhaled corticosteroids at 
constant doses and rescue use 
of short acting β2 agonists 
allowed.
Gupta, 2002[29] 
Parallel
4 33 patients with FEV1 < 60 % 
predicted and FEV1/FVC ≤ 
70%; reversibility <12 % 
improvement of FEV1 after 400 
µg salbutamol
Salmeterol (50 µg twice daily) 
or placebo twice daily for 8 
weeks
FEV1, FVC, six minute walk 
test, HRQoL on SF-36[28], 
dyspnoea on BDI, patient self-
assessment, and rescure 
inhaler usage
Two week run in period. 
Patients required to take 
beclomethasone 400 µg twice 
daily and ipratropium 20 µg 
four times daily.
Mahler, 2002[30] 
Parallel
2 158 patients with FEV1 < 65 % 
predicted and FEV1/FVC ≤ 
70%; reversibility <12 % 
improvement of FEV1 after 400 
µg salbutamol
Salmeterol (50 µg twice daily) 
or placebo twice daily for 24 
weeks
FEV1, morning PEF, dyspnoea 
on BDI and TDI; rescue 
salbutamol use; HRQoL on 
CRDQ [30]; symptoms on 
CBSQ
Randomization stratified by 
reversibility.
Calverly, 2003[28] 
Parallel
5 733 patients with FEV125–70% 
predicted and FEV1/FVC ≤ 
70%; reversibility <10 % of 
predicted FEV1 after salbutamol
Salmeterol (50 µg twice daily) 
or placebo twice daily for 52 
weeks
FEV1, FVC, relief medication, 
symptom scores, night-time 
awakenings, exacerbation 
rates, HRQoL on SGRQ
Two week run in and two 
week follow up
Hanania, 2003[31] 
Parallel
2 163 patients with FEV1 < 65% 
predicted but > 700 ml (or if ≤ 
700 ml > 40 % predicted) and 
FEV1/FVC < 65%; reversibility 
< 12 % of predicted FEV1 after 
salbutamol
Salmeterol (50 µg twice daily) 
or placebo twice daily for 24 
weeks
FEV1, morning PEF, dyspnoea 
on BDI and TDI; rescue 
salbutamol use; HRQoL on 
CRDQ [30]; symptoms on 
CBSQ, exacerbation rates (all 
severities)
Randomization stratified by 
reversibility
AUC = area under the curve; BDI = baseline dyspnoea index;[29] CBSQ = chronic bronchitis symptom questionnaire; [42] CRDQ = chronic 
respiratory disease questionnaire;[30] FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; HRQoL = health related quality 
of life; MMRC = Modified Medical Research Council; PEFR = peak expiratory flow rate; RV = residual volume; SF-36 = Medical Outcomes Study 
Short Form 36;[28] SGRQ = St. George's Respiratory Questionnaire;[27] TDI = transition dyspnoea index;[29] TLC = total lung capacity.BMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
Page 7 of 11
(page number not for citation purposes)
trial reporting data [15] found a median (interquartile
range) distance in six minutes of 450 (371–491) m for
placebo recipients and 425 (392–473) m for salmeterol
recipients; the difference was not reported to be signifi-
cant, but the patients receiving salmeterol (50 µg twice
daily) perceived significantly less exertion by the end of
treatment, as measured on the Borg scale [median (inter-
quartile range) 0.5 (0–1) for salmeterol versus 1 (0–2) for
placebo, p = 0.004] [32]. A 16 week trial [10] found a sig-
nificant (p < 0.05) reduction in postwalk breathlessness
(three or more points on the 10 point Borg scale) after
eight and 16 weeks of 50 µg but not 100 µg of salmeterol
twice daily, compared with placebo (OR 0.62 [95% CI
0.42 to 0.91]). Similarly, an 8+8 (8 weeks then crossover
then 8 additional weeks) week trial [22] did not detect a
significant (p > 0.05) difference in postwalk breathless-
ness between patients receiving 100 µg of salmeterol and
those receiving placebo.
One study comparing formoterol, ipratropium, and pla-
cebo [26] reported mean changes in walking distance
from baseline to endpoint, measured with the shuttle
Table 2: Selected results
First author FEV1 Symptom scores (lower is better)
Salmeterol versus placebo
Ulrik[16] No significant differences in reversibility of percent predicted FEV1 
with treatment. Mean (SE): 2.7% (0.4) versus 3.4% (0.4).
Significant differences in median (range) symptom scores during 
treatment.
Daytime (scale 0–5): 1.0 (0–3.4) versus 1.8 (0.1–4.0).
Night-time (scale 0–4): 0.9 (0–3.4) versus 1.6 (0.1–4.0).
Newman[22] No significant differences in measurements with treatment (data not 
reported).
Symptoms significantly reduced during salmeterol compared with 
placebo treatment.
Scale and scores not reported.
Grove[15] Significant differences one and six hours after single dose and six 
hours after four weeks of treatment. Mean change: 120 versus 10 ml 
after four weeks.
Boyd[10] Significant differences in improvement with treatment. Mean 
difference (95% CI): for salmeterol 50 µg versus placebo 97.80 (55.6 
to 139.99) ml; for salmeterol 100 µg versus placebo 117.60 (67.88 to 
167.32) ml.
Significant difference in distribution of median daytime and night-time 
symptom scores between active treatment and placebo groups (CI 
0.0 to 0.0 in all cases) but not between active treatment groups.
Daytime (scale 0–5): baseline, 2 in each group; from week 5, 1 in 
active treatment groups and 2 in placebo group.
Night-time (scale 0–4): baseline, 1 in placebo and salmeterol 50 µg 
groups and 0 in salmeterol 100 µg group; from week 1, 0 in 
salmeterol 50 µg group and no change in other groups.
Jones[14] (Presented QoL results for subset of patients described in Boyd[10].)
Gupta[29] A mean increase in predose FEV1 of 170 ml (distibution not 
reported) for salmeterol vs. a mean decrease of 20 ml (distribution 
not reported) for placebo after 8 weeks.
Both salmeterol and placebo produced significant improvemnts in 
BDI scores, however the magnitude of increase was greater vs. 
placebo (3 vs. 1); 100% patients treated with salmeterol reported 
decreased cough and dyspnea vs. 69% (11/16) of placebo recipients
Mahler 2002 [30] A mean increase of 80 ml (95%CI 35 to 125) for salmeterol vs. mean 
decrease of -8 ml (95%CI: -53 to 37) for placebo. Two-hour post-
dose FEV1 mean increase of 175 ml (95%CI: 116 to 234) vs. mean 
increase of 28 ml (95%CI: -17 to 73)
Mean increase of 0.5 (SE 0.4) in TDI for salmeterol recipients and 0.4 
(SE 0.3) for placebo recipients. Not clinically or statistically significant.
Calverly [28] A mean increase in predose FEV1of 25 ml vs. a mean decrease of -38 
ml (P < 0.05) in salmeterol and placebo recipients. Smaller difference 
for two-hour post-dose FEV1 (data not reported).
Mean scores for cough (scale 0–3); breathlessness (scale 0 to 4); 
sputum production (scale 0 to 3); sputum colour (scale 0 to 4): 
salmeterol: cough 1.36 (SE0.03); breathlessness 1.59 (0.03); sputum 
production 1.30 (0.03) and colour 1.35 (0.03) vs. placebo: cough 1.44 
(0.03); breathlessness 1.66 (0.03), sputum production 1.34 (0.03) and 
colour 1.36 (0.03).
Hanania[31] A mean increase of 26 ml (95%CI: -27 to 79) for salmeterol vs. mean 
increase of 19 ml (95%CI: -26 to 64) for placebo. Two-hour post-
dose FEV1 mean increase of 119 ml (95%CI: 70 to 168) vs. mean 
increase of 71 ml (95%CI: 24 to 118)
The magnitude of TDI responses was less in non-reversible vs. 
reversible patients. (Data are not reported)
Salmeterol versus ipratropium versus placebo
Mahler[8] Significant differences between active treatment and placebo groups 
but not between active treatment groups. Peak improvements with 
treatment: 155, 165, and 24 ml, respectively.
No significant differences in change of mean daytime symptom score 
with treatment. No significant differences in TDI except between 
ipratropium and placebo groups at week 8.
After 12 weeks, mean TDI 0.35, 0.98, and 0.48, respectively.
Rennard[23] Significant differences between active treatment and placebo groups 
but not between active treatment groups. FEV1AUC 0–12 hour 
responses significantly greater with salmeterol and ipratropium than 
with placebo (data not reported).
Formoterol versus placebo
Rossi[27] Significant differences in estimated difference in FEV1AUC 0–12 hour 
responses: between formoterol 12 µg and placebo groups, 145 ml; 
between formoterol 24 µg and placebo groups, 141 ml. (Individual 
values for treatment groups not available.)
Formoterol versus ipratropium versus placebo
Stahl[26] Significant differences in improvement in percent predicted 
FEV1between active treatment and placebo groups but not between 
active treatment groups: 13%, 7%, and 6%, respectively.
Significant differences between active treatment and placebo groups 
in change from baseline in breathlessness (scored 0 to 4 morning and 
evening). Means: -0.21, -0.29, and 0.0, respectively.
CI = confidence interval; SE = standard error.BMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
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walking test, of 19.2, 17.5 and 5.1 m, respectively; the dif-
ferences were not significant (p > 0.05).
Dyspnea
In several trials [10,16,22,26,28-31] the patients assessed
symptom severity every day, generally using ordinal
scales. One 12 week trial comparing salmeterol, ipratro-
pium, and placebo [8] measured the severity of dyspnea at
baseline with a multidimensional baseline dyspnea index
(BDI) and changes in severity every two weeks with a TDI
[33]. As table 2 shows, some differences during treatment
with an active drug as compared with placebo were signif-
icant and others were not.
Rescue use of a short acting β2 agonist
In five of six trials salmeterol treatment was associated
with less salbutamol use than was placebo treatment
[10,16,22,28,29] In one trial (4+4 weeks) [16] the median
numbers (range) of daytime rescue doses were 1.7 (0–6.1)
and 2.6 (0–7.9), respectively, and the median numbers of
night-time doses 0 (0–4.2) and 0.3 (0–5.0). In a 52 week
trial.[28], the median number of rescue inhalations per
day was 2 for both salmeterol and placebo recipients, but
these groups were statistically different (p = 0.028).
Another trial[29] reported the mean number of doses of
rescue salbutamol was significantly lower during treat-
ment in salmeterol recipients (0.59, 95%CI: 0.30 to 0.88)
versus placebo recipients (1.75, 95%CI: 1.33 to 2.17).
In one 12 week trial comparing salmeterol, ipratropium,
and placebo [8] no significant difference was observed in
additional bronchodilator use between the placebo and
active drug groups.
Quality of life
HRQoL was evaluated in four trials[14,26,28,29] In a sal-
meterol study [14] a subset of a larger patient group was
asked to complete the disease-specific SGRQ [34] and the
Medical Outcomes Study Short Form 36 (SF-36) [35] at
baseline and after 16 weeks of treatment. The SGRQ has
three components: distress due to respiratory symptoms,
effects of disturbances on mobility and physical activity,
and psychosocial impact of the disease; negative changes
represent improvement. Data from 283 patients (95 in the
placebo group and 94 in each salmeterol group) were ana-
lysed; data for others were excluded because of noncom-
pletion of one or both questionnaires at 16 weeks or
inability to meet quality control criteria or both. Salme-
terol 50 µg (but not 100 µg) twice daily was associated
with significantly greater improvement in mean (standard
deviation) SGRQ scores from baseline to endpoint than
was placebo: -6.8 (13.2) versus -1.4 (11.7) for total score
and -8.0 (17.6) versus 0.0 (15.7) for impact score. No sig-
nificant differences between placebo and either dose of
salmeterol were observed in any of the domains of the SF-
36 except for "role-emotional": these scores were signifi-
cantly worse for recipients of salmeterol 100 µg than for
recipients of placebo.
In the 52 week study).)[28], health status was assessed
with the SGRQ. The adjusted mean score was not statisti-
cally different in salmeterol recipients, at 45.2 (95%CI:
44.4 to 46.0) versus placebo recipients, at 46.3 (95%CI:
45.3 to 47.2). In an 8 week study[29] the magnitude of
improvement for salmeterol versus placebo recipients
rated on an SF-36 scale was significantly greater for the
dimensions of "general health" (p = 0.008), "health
change" (p = 0.026); physical functioning" (p = 0.008)
and "vitality energy and fatigue" (p = 0.008)
In the trial comparing formoterol, ipratropium, and pla-
cebo [26] HRQoL was also evaluated with the disease spe-
cific SGRQ. Of the 183 patients, 144 completed the
assessment; reasons for not doing so were not reported.
The changes from baseline to endpoint in total score were
negligible in all three groups, at 0.0, -0.5, and 1.5,
respectively.
COPD exacerbations
Three trials[10,22,28] reported on this outcome; only one
trial).)[28] defined "COPD exacerbation" as episodes that
required antibiotics or corticosteroids but not hospital
admission; these occurred at a mean rate of 0.54 exacerba-
tions/patient/year in salmeterol recipients and 0.76 exac-
erbations/patient/year in placebo recipients (p = 0.0003).
In one 16 week trial [10] the numbers (and proportions)
of patients having exacerbations among those receiving
salmeterol 50 or 100 µg twice daily or placebo were 75
(33%), 91 (42%), and 98 (43%), respectively. In an 8+8
week trial [22] there were fewer exacerbations during
treatment with salmeterol 100 µg twice daily than during
treatment with placebo (p = 0.065); data were not
presented.
Adverse Effects
Data on adverse effects of interest were not available from
the reports.
Discussion
We identified thirteen reports of twelve randomized con-
trolled trials describing the effect of administering the
long acting β2-agonists, salmeterol and formoterol, to
patients with poorly reversible COPD.
It is not clear from the reports whether the twelve selected
trials had sufficient power to detect significant differences
between treatment and control groups in the various sub-
jective and objective outcome measures. Since data were
not pooled for meta-analysis, we were not able to conduct
a sensitivity analysis based on the quality of trial report-BMC Pulmonary Medicine 2004, 4:7 http://www.biomedcentral.com/1471-2466/4/7
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ing. Accordingly, we cannot comment on the possible
influence of quality on the effect size of the outcome
measures. Clinical heterogeneity among the trials limited
assessment of the overall effect of the interventions. Since
we did not perform a meta-analysis, statistical heterogene-
ity was not an issue.
We selected reports that met our inclusion criteria, regard-
less of publication status, language and trial quality using
a systematic research methodology; this approach has
been shown to minimize potential selection and publica-
tion bias and lead to more reliable conclusions[36] We
made every effort to conduct our review and report its
results with the highest rigour.
A potential limitation of our research is that we did not
seek trials comparing long acting β2-agonists marketed
outside of Canada (e.g., bambuterol) or those trials com-
paring long acting β2-agonists to agents other than iprat-
ropium and placebo (e.g., short-acting β2-agonists,
methylxanthines). Similarly, we excluded those trials in
which the FEV1 response to a bronchodilator was not
reported or greater than 15%. Thus, our results may not be
generalisable to the greater population of patients who
can be currently defined as having COPD[18]. We plan to
include a greater number of comparators and a broader
population in an upcoming analysis[37]
Our results are similar to those of an earlier review [12]
that identified three placebo controlled trials included in
our review, but there are two important differences. In the
earlier review FEV1 endpoint data from the placebo and
salmeterol groups in two crossover trials [15,16] were
pooled; the weighted mean differences were not signifi-
cant. We preferred to analyse net improvement in FEV1
(the difference from baseline to endpoint), as we felt that
it more accurately reflected the impact of maintenance
therapy. In addition, no trials comparing long acting β2
agonists and ipratropium were available at the time of the
earlier review.
Another review has recently been published.[38] How-
ever, these authors restricted their search to MEDLINE and
failed to identify a clinical trial comparing formoterol
with ipratropium.[26] As a consequence, the evidence
describing the use of formoterol versus ipratropium is
limited to a single trial.[39] In contrast, we opted to
exclude this trial after identifying two trials because
roughly 40% of patients exhibited partial reversibility of
FEV1 (15% to 80%) to an inhaled dose of 200 mcg salb-
utamol at baseline. We are in agreement with the authors'
summary of the evidence surrounding salmeterol versus
ipratropium.
We believe our findings are in accord with current guide-
lines, such as the GOLD guidelines, that suggest bron-
chodilators should be prescribed according to individual
patient responses. However, policymakers with limited
health service resources need to be aware of an identifia-
ble sub-population of patients with poorly reversible
COPD for which long acting β2-agonists may result in
reduced efficiency (cost-effectiveness).
Our research also suggests clinical investigators of COPD
trials should stratify trial participants into groups for
which outcomes may consistently differ. Of the trials
identified, four[23,30,31,40] used this approach. Out-
come information from patients with poor reversibility
was also analyzed in an abstract[41] of an excluded trial
but not in the published report.[39] We were unable to
ascertain sufficient details surrounding this analysis to
add it to our findings.
Conclusions
In terms of clinical outcomes and safety, we could not find
convincing evidence that salmeterol and formoterol have
demonstrated advantages to ipratropium, a less expensive
drug, for patients with stable COPD and poor reversibil-
ity. Compared to placebo, we found evidence of reduced
rescue inhaler usage and improved spirometric outcomes
without a significant impact on quality of life or exercise
capacity.
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